Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10962425 | Vaccine | 2016 | 7 Pages |
Abstract
The AdAg85A generated from the 3Â L and 60Â L bioreactor runs was purified through several purification steps. More than 98% of total cellular proteins was removed, over 60% of viral particles was recovered after the purification process, and purity of AdAg85A was similar to that of the ATCC VR-1516 Ad5 standard. Vaccination of mice with the purified AdAg85A demonstrated a very good level of Ag85A-specific antibody responses. The optimized production and purification conditions were transferred to a GMP facility for manufacturing of AdAg85A for generation of clinical grade material to support clinical trials.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Chun Fang Shen, Danielle Jacob, Tao Zhu, Alice Bernier, Zhongqi Shao, Xuefeng Yu, Mehul Patel, Stephane Lanthier, Amine Kamen,